|
|
| | Sitagliptin phosphate monohydrate Basic information |
| Product Name: | Sitagliptin phosphate monohydrate | | Synonyms: | Sitagliptin Phosphate.H2O;Sitagliptin Monophosphate Monohydrate;(R)-3-AMino-1-(3-(trifluoroMethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate hydrate;Sitaglipin Phosphate Monohydrate;(R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate monohydrate;(R)-3-Amino-1-(3-(trifluor;Sitagliptin posphate monohydrate;Sitagliptin phosphate monohydrate, 97%, DPP-IV inhibitor | | CAS: | 654671-77-9 | | MF: | C16H20F6N5O6P | | MW: | 523.32 | | EINECS: | 682-492-2 | | Product Categories: | Inhibitors;Inhibitor;API;APIs;654671-77-9 | | Mol File: | 654671-77-9.mol |  |
| | Sitagliptin phosphate monohydrate Chemical Properties |
| Fp | 274.3℃ | | storage temp. | 2-8°C | | solubility | ≥23.8 mg/mL in DMSO; insoluble in EtOH; ≥30.6 mg/mL in H2O with ultrasonic | | form | solid | | color | White to off-white | | Optical Rotation | -5.53°(C=0.60g/100mL, NAOH, 20°C, 589nm) | | Major Application | pharmaceutical (small molecule) | | InChIKey | IQFYVLUXQXSJJN-OVMXBOEKNA-N | | SMILES | P(O)(O)(O)=O.C(C1=NN=C2CN(C(=O)C[C@H](N)CC3C=C(F)C(F)=CC=3F)CCN12)(F)(F)F |&1:15,r| | | CAS DataBase Reference | 654671-77-9(CAS DataBase Reference) |
| | Sitagliptin phosphate monohydrate Usage And Synthesis |
| Chemical Properties | white crystalline | | Uses | antimuscarinic | | Uses | Sitagliptin Phosphate Monohydrate is a dipeptidyl peptidase-IV (DPPIV) inhibitor. | | Biological Activity | sitagliptin phosphate monohydrate is the phosphate salt of its active component, sitagliptin, with one molecule of water. sitagliptin is a potent inhibitor of dipeptidyl peptidase 4 (dpp-4), an enzyme catalyzing the cleavage of peptides with an n-terminal alanine or proline amino acid residue, that selectively inhibits dpp-4 with 50% inhibition concentration ic50 value of 18 nm and shows no affinity towards other ddp enzymes (such as ddp-8 and ddp-9). the inhibition of dpp4 by sitagliptin has been found to be mediated by increasing levels of two dpp-4 substrates, including glucagon-like peptide-1 (glp-1) and gastric inhibitory polypeptide (gip). sitagliptin is currently being investigated in the treatment of type ii diabetes.gallwitz b. review of sitagliptin phosphate: a novel treatment for type 2 diabetes. vasc health risk manag. 2007;3(2):203-10. | | Synthesis | The general procedure for the synthesis of (R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one as a raw material and its phosphate hydrate was carried out in the following manner: 8.14 g of (R)-3-amino-1-( 3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one, 16.3 mL of isopropanol, and 7.3 mL of water, followed by the slow dropwise addition of 1.73 mL of 85% (v/v) phosphoric acid aqueous solution. The temperature of the reaction system was raised to 80 °C until complete dissolution to form a clear solution. The solution was then cooled to 70 °C and the reaction was continuously stirred at this temperature for 2 hours. Upon completion of the reaction, the mixture was cooled to 54 °C at a rate of 8 °C/h and then continued to cool to 22 °C at a rate of 16 °C/h, at which point a large amount of white solid precipitated. 57 mL of isopropanol was added slowly over a period of 40 minutes and stirring was continued for 15 minutes after addition. The white solid was collected by diafiltration and washed twice with 40.7 mL of mixed isopropanol-water solvent (V/V=11:1). Finally, the product was dried under vacuum at 25 °C and -0.08 MPa for 5.5 h to give 10.22 g of white crystalline solid. The purity was 99.91% by HPLC, the moisture content was 3.54% and the molar yield was 97.7%. | | target | DPP-4 | | References | [1] Patent: CN105175422, 2018, B. Location in patent: Paragraph 0070; 0077; 0080; 0083; 0086; 0089; 0092; 0095 [2] Synthetic Communications, 2013, vol. 43, # 24, p. 3281 - 3286 [3] Patent: WO2006/33848, 2006, A1. Location in patent: Page/Page column 14 [4] Patent: WO2005/30127, 2005, A2. Location in patent: Page/Page column 13 [5] Patent: US2013/158265, 2013, A1. Location in patent: Paragraph 0204 |
| | Sitagliptin phosphate monohydrate Preparation Products And Raw materials |
|